CJC-1295: The Complete 2026 Guide to Dosing, Benefits & Stacking

CJC-1295 has become one of the most prescribed peptides at longevity clinics and functional medicine practices — and for good reason. As a synthetic growth hormone-releasing hormone (GHRH) analog, it offers a practical way to amplify the body's natural GH pulses without the blunt pharmacology of synthetic HGH. But like all peptides, the details matter: which form you use, how you dose it, who you stack it with, and what the actual evidence says.

This guide covers all of it.

What Is CJC-1295?

CJC-1295 is a 30-amino acid synthetic peptide designed to mimic and improve upon natural GHRH — the hypothalamic signal that tells the pituitary to release growth hormone. It was originally developed by ConjuChem Biotechnologies in the early 2000s as a potential treatment for GH deficiency.

What makes CJC-1295 different from native GHRH is structural: key amino acid substitutions at positions 2, 8, 15, and 27 protect the molecule from rapid breakdown by dipeptidyl peptidase-4 (DPP-4), an enzyme that normally degrades GHRH within minutes of release. This dramatically extends the active window of the peptide.

CJC-1295 exists in two distinct variants that behave quite differently in practice — which is one of the most important distinctions any user or clinician needs to understand.

CJC-1295 With DAC vs. Without DAC

CJC-1295 Without DAC (Modified GRF 1-29)

The original form. Without the Drug Affinity Complex, CJC-1295 has a half-life of approximately 30 minutes. This produces a discrete GH pulse that rises and falls within an hour or two — closely mimicking the natural pulsatile pattern of GH secretion.

This pulsatile pattern matters. Research in the Journal of Clinical Endocrinology and Metabolism found that pulsatile GH administration produced 40-60% greater lipolytic (fat-burning) response compared to continuous infusion at equivalent cumulative doses. For these reasons, CJC-1295 without DAC is generally preferred in clinical settings — particularly when stacked with a GHRP like Ipamorelin.

CJC-1295 With DAC

The DAC (Drug Affinity Complex) is a lysine-maleimide linker that allows CJC-1295 to bind reversibly to albumin in the bloodstream — effectively turning the peptide into a long-acting depot. This extends the half-life to 6-8 days, meaning a single injection sustains elevated GH and IGF-1 for close to a week.

The trade-off is that this continuous, non-pulsatile stimulation differs significantly from physiological GH secretion. Some clinicians argue it is better suited for individuals with significant GH deficiency, while others prefer the no-DAC version for its more natural kinetics.

Mechanism of Action

Both forms work through the same underlying pathway: binding to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary. This stimulates:

1. Increased cAMP production via Gs protein signaling
2. Calcium influx into the cell
3. Exocytosis of GH-containing secretory granules
4. Downstream IGF-1 synthesis in the liver

CJC-1295 does not suppress the somatostatin feedback loop directly — it simply amplifies the signal when somatostatin is not dominant. This is one reason stacking with a GHRP is so effective: GHRPs like Ipamorelin actively suppress somatostatin, while CJC-1295 amplifies the GHRH signal. Together, they produce a synergistic GH pulse larger than either peptide alone.

What the Clinical Research Actually Shows

Three key clinical studies establish the pharmacological foundation for CJC-1295:

Teichman et al. (2006) in the Journal of Clinical Endocrinology and Metabolism — the pivotal phase I/II trial — found that a single subcutaneous injection of CJC-1295 DAC produced dose-dependent GH increases of 2- to 10-fold above baseline for 6 days or longer. IGF-1 levels increased 1.5- to 3-fold and remained elevated for 9-11 days. The peptide was well-tolerated across all dose cohorts.

Ionescu and Frohman (2006) confirmed sustained GH/IGF-1 elevation after multiple injections, with mean IGF-1 levels remaining above baseline for up to 28 days in some participants.

Sackmann-Sala et al. (2009) demonstrated measurable changes in serum protein profiles associated with GH/IGF-1 axis activation in normal adult subjects after CJC-1295 administration.

Important caveat: None of these trials measured body composition, exercise performance, or recovery outcomes directly. The clinical program was halted after a patient death unrelated to efficacy, and ConjuChem never completed phase III trials. Every claim about muscle gain, fat loss, and sleep improvement is biologically plausible — extrapolated from GH/IGF-1 physiology — but has not been validated in controlled human outcome trials. CJC-1295 is a research compound with strong mechanistic rationale, not an FDA-approved therapeutic with outcome data.

Benefits: What GH/IGF-1 Elevation Actually Does

Despite the absence of body composition trials specific to CJC-1295, decades of GH physiology research tell us what sustained GH and IGF-1 elevation tends to produce:

Lean Muscle Support

IGF-1 activates the PI3K/Akt/mTOR pathway in skeletal muscle, driving satellite cell activation, protein synthesis, and muscle fiber hypertrophy. In individuals with suboptimal GH output — common after age 35 — restoring GH pulsatility may support lean mass maintenance.

Fat Metabolism

GH directly stimulates lipolysis in adipocytes by activating hormone-sensitive lipase, preferentially mobilizing visceral fat. The pulsatile pattern produced by no-DAC + Ipamorelin is thought to be especially favorable for lipolytic signaling.

Connective Tissue and Recovery

IGF-1 promotes collagen synthesis and fibroblast proliferation — mechanisms relevant to tendon, ligament, and joint health. This makes GH secretagogue stacks particularly interesting for athletes recovering from soft-tissue injuries.

Sleep Quality

The largest natural GH pulse occurs during slow-wave (deep) sleep. Peptides that amplify GH secretion may reinforce this cycle, and many users report improved sleep depth and recovery — though this remains largely anecdotal.

Bone Density

GH and IGF-1 promote osteoblast activity and bone matrix formation. While CJC-1295 has not been studied specifically for osteoporosis, GH's role in bone maintenance is well-established in the endocrinology literature.

Dosing Protocols

CJC-1295 Without DAC (Preferred Clinical Protocol)

CJC-1295 With DAC

Insulin and elevated blood glucose suppress GH release. Injecting on an empty stomach — away from carbohydrate-heavy meals — optimizes the GH pulse. Many practitioners recommend a 2-hour fast before and after injection.

Stacking: CJC-1295 + Ipamorelin (The Gold Standard)

The most widely used and clinically supported combination is CJC-1295 without DAC paired with Ipamorelin. Here is why this stack works so well:

• CJC-1295 no DAC activates GHRHR on pituitary somatotrophs, providing the "release" signal
• Ipamorelin binds to ghrelin receptors (GHSR1a) and simultaneously suppresses somatostatin — removing the primary brake on GH release

The result is a GH pulse that is both amplified and sustained compared to either peptide alone — without the cortisol elevation, prolactin increase, or hunger stimulation associated with older GHRPs like GHRP-6.

Standard combined protocol:

• CJC-1295 no DAC: 100-200 mcg
• Ipamorelin: 200-300 mcg
• Injected together, subcutaneously, 1-2x daily

Some practitioners also stack CJC-1295 with GHRP-2 for a more aggressive GH pulse, though GHRP-2 does carry some cortisol and prolactin stimulation at higher doses.

Side Effects and Safety Profile

Water Retention: The most frequent complaint. GH promotes sodium and water retention via renal mechanisms, leading to mild puffiness in the hands, feet, and face. Typically dose-dependent and improves over time or upon discontinuation.

Injection Site Reactions: Mild redness, swelling, or discomfort — standard for subcutaneous peptide administration.

Headache and Flushing: Reported in a subset of users, typically shortly after injection and resolving within hours.

Tingling or Numbness: Transient paresthesia in the extremities, likely related to fluid shifts and GH effects on peripheral nerves.

Receptor Desensitization: Continuous or excessive stimulation of GHRHR can reduce receptor sensitivity over time. This is why cycling — typically 3 months on, 1 month off — is standard practice. It preserves receptor responsiveness and prevents tolerance.

Unlike GHRP-6 or synthetic HGH, CJC-1295 combined with Ipamorelin does not significantly elevate cortisol, aldosterone, or prolactin at standard doses. This is a meaningful advantage over older GH secretagogue protocols.

Regulatory and Compounding Status (2026)

CJC-1295 has never received FDA approval for any indication. As of late 2024, the FDA removed CJC-1295 from Category 2 of its interim 503A bulk drug substance list — the category for substances that may present significant safety risks. However, this removal did not automatically authorize compounding; instead, it triggered a formal review by the Pharmacy Compounding Advisory Committee (PCAC).

Practically, this means:

• 503A pharmacies (traditional compounding pharmacies serving individual patients) cannot currently compound CJC-1295 while PCAC review is ongoing
• 503B outsourcing facilities operate under a separate regulatory framework
• The RFK Jr.-era HHS has signaled interest in expanding compounded peptide access — the landscape may shift in 2026

If you are working with a compounding pharmacy or telehealth clinic prescribing CJC-1295, verify that your provider is current on FDA guidance and PCAC status.

Who Is CJC-1295 For?

CJC-1295 is typically considered in research or clinical contexts for:

• Adults over 35 experiencing age-related decline in GH and IGF-1
• Athletes focused on recovery, lean body composition, and connective tissue health
• Individuals with low IGF-1 on bloodwork who are not candidates for synthetic HGH
• Those seeking improved sleep quality and general recovery

It is not appropriate for individuals with active malignancies, pituitary tumors, or conditions sensitive to GH stimulation. Baseline IGF-1 testing before and during use is strongly recommended.

Reconstitution and Storage

CJC-1295 is supplied as a lyophilized (freeze-dried) powder. To reconstitute:

• Add 1-2 mL of bacteriostatic water slowly to the vial using a syringe
• Swirl gently — do not shake
• Store reconstituted peptide refrigerated at 2-8 degrees Celsius
• Use within 28-30 days of reconstitution
• Protect from light and heat; do not freeze once reconstituted

Final Thoughts

CJC-1295 occupies a unique position in the peptide space: it is backed by genuine clinical pharmacology data, has a well-characterized safety profile, and addresses a real biological decline — age-related GH reduction — through a mechanism that respects the body's natural pulsatile architecture, especially when used without DAC.

The limitations are real too: no published outcome trials on body composition, an unsettled regulatory status, and the need for careful cycling to avoid desensitization. Anyone considering CJC-1295 should approach it with realistic expectations, proper lab monitoring, and sourcing through reputable, compliant channels.

When used thoughtfully — particularly in a CJC-1295/Ipamorelin stack — it represents one of the more scientifically credible tools in the GH optimization toolkit available today.

This article is for educational purposes only and does not constitute medical advice. CJC-1295 is not FDA-approved for therapeutic use. Consult a qualified healthcare provider before using any peptide.